copper tripeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
Some females stay and defend the nest until the chicks start hatching, but most leave the nesting area completely to nest again; in a good season, a female emu may nest three times. If the parents stay together during the incubation period, they will take turns standing guard over the eggs while the other drinks and feeds within earshot. If it perceives a threat during this period, it will lie down on top of the nest and try to blend in with the similar-looking surrounds, and suddenly stand up to confront and scare the other party if it comes close. Incubation takes 56 days, and the male stops incubating the eggs shortly before they hatch. The temperature of the nest rises slightly during the eight-week period. Although the eggs are laid sequentially, they tend to hatch within two days of one another, as the eggs that were laid later experienced higher temperatures and developed more rapidly. During the process, the precocial emu chicks need to develop a capacity for thermoregulation. During incubation, the embryos are kept at a constant temperature but the chicks will need to be able to cope with varying external temperatures by the time they hatch. Newly hatched chicks are active and can leave the nest within a few days of hatching. They stand about 12 cm (5 in) tall at first, weigh 0.5 kg (17.6 oz), and have distinctive brown and cream stripes for camouflage, which fade after three months or so. The male guards the growing chicks for up to seven months, teaching them how to find food.
The two substrates of this enzyme are (-)-ureidoglycolic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are oxaluric acid, reduced NADH, and a proton. This enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-ureidoglycolate:NAD(P)+ oxidoreductase. This enzyme participates in purine metabolism.
Similarly, the number of one-year-olds fully immunised against measles rose from 30% in 1985–1990 to 40% in 2000–2005, and for tuberculosis, it grew nearly 20% from 31% to 50% over the same period. The number of infants with low birth weight fell from 16 per 1,000 to 0.3, a 15% drop in total over the same time frame. Between 2005 and 2010 as compared to the 1985–1990 period, infant mortality per 1,000 births also fell from 152 to 109.6. Significantly, maternal mortality per 100,000 births fell from 1,600 in the pre-war 1985–1990 half-decade to 1,100 in the 2000–2005 period. The number of physicians per 100,000 people also rose from 3.4 to 4 over the same time frame, as did the percentage of the population with access to sanitation services, which increased from 18% to 26%. According to United Nations Population Fund data on the midwifery workforce, there is a total of 429 midwives (including nurse-midwives) in Somalia, with a density of one midwife per 1,000 live births. Eight midwifery institutions presently exist in the country, two of which are private. Midwifery is regulated by the government, and a licence is required to practice professionally. A live registry is also in place to keep track of licensed midwives. In addition, midwives in the country are officially represented by a local midwives association, with 350 registered members. According to a 2005 World Health Organization estimate, about 97.9% of Somalia's women and girls underwent female genital mutilation, a pre-marital custom mainly endemic to the Horn of Africa and parts of the Near East.
Sources: en.wikipedia.org
In 1994, an EU scientific commission was asked to report on the incidence of mastitis and other disorders in dairy cows and on other aspects of their welfare. The commission's statement, subsequently adopted by the EU, stated that the use of rBST substantially increased health problems with cows, including foot problems, mastitis, and injection site reactions, impinged on the welfare of the animals, and caused reproductive disorders. The report concluded, on the basis of the health and welfare of the animals, rBST should not be used. Health Canada prohibited the sale of rBST in 1999; the external committees found that there was health risk to humans, and the drug present a threat to animal health, and, for this reason, cannot be sold in Canada. Monsanto-sponsored trials reviewed by the FDA asked whether the use of rBST makes cows more susceptible to mastitis. According to the FDA, which used data from eight Monsanto-sponsored trials in its decision in 1993 to approve Monsanto's rBST product, the answer is yes. The data from these eight trials, which involved 487 cows, showed that during the period of rBST treatment, mastitis incidence increased by 76% in primiparous cows and by 50% for multiparous cows. Overall, the increase was 53%. Conversely, however, a study from the University of Georgia on the monitoring post-approval of rBST, showed that there was no statistically significant (P > 0.05) derivation in cases of clinical mastitis in dairy cows treated with rBST.
Good Glue Sticks (French: La Colle universelle, literally "The Universal Glue") is a 1907 French short silent film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 1005–1009 in its catalogues. Méliès plays the street peddler in the film, which uses substitution splices for its special effects. The earliest academic discussion of the film, in John Frazer's 1979 book Artificially Arranged Scenes: The Films of Georges Méliès, was based on a badly edited print, with the end of the film placed at the beginning. A 1981 guide to Méliès's films, published by the Centre national de la cinématographie, clarified the scene order.
The pathway of wing expansion is regulated by a signal-receptor pathway, where the neurohormone bursicon interacts with its complementary G protein-coupled receptor; this receptor drives one of the G-protein subunits to signal further enzyme activity and results in development in the wing, such as apoptosis and growth. se: sepia – The eye color of the sepia mutant is sepia, a reddish-brown color. In wild-type flies, ommochromes (brown) and drosopterins (red) give the eyes the typical red color. The drosopterins are made via a pathway that involves a pyrimidodiazepine synthase, which is encoded on chromosome 3L. The gene has a premature stop codon in sepia flies, so that the flies cannot produce the pyrimidodiazepine synthase and thus no red pigment, so that the eyes stay sepia. The sepia allele is recessive and thus offspring from sepia flies and homozygous wild type flies, has red eyes. The sepia phenotype does not depend on the sex of the fly. v: vermilion – The vermilion mutants cannot produce the brown ommochromes leaving the red drosopterins so that the eyes are vermilion colored (a radiant red) compared to a wild-type D. melanogaster. The vermilion mutation is sex-linked and recessive. The gene that is defective lies on the X chromosome. The brown ommochromes are synthesised from kynurenine, which is made from tryptophane. Vermilion flies cannot convert tryptophane into kynurenine and thus cannot make ommochromes, either. Vermilion mutants live longer than wild-type flies.
Aspartate kinase catalyzes the initial step in the diaminopimelic acid pathway by transferring a phosphoryl from ATP onto the carboxylate group of aspartate, which yields aspartyl-β-phosphate. Aspartate-semialdehyde dehydrogenase catalyzes the reduction reaction by dephosphorylation of aspartyl-β-phosphate to yield aspartate-β-semialdehyde. Dihydrodipicolinate synthase catalyzes the condensation reaction of aspartate-β-semialdehyde with pyruvate to yield dihydrodipicolinic acid. 4-hydroxy-tetrahydrodipicolinate reductase catalyzes the reduction of dihydrodipicolinic acid to yield tetrahydrodipicolinic acid. Tetrahydrodipicolinate N-succinyltransferase catalyzes the transfer of a succinyl group from succinyl-CoA on to tetrahydrodipicolinic acid to yield N-succinyl-L-2,6-diaminoheptanedioate. N-succinyldiaminopimelate aminotransferase catalyzes the transfer of an amino group from glutamate onto N-succinyl-L-2,6-diaminoheptanedioate to yield N-succinyl-L,L-diaminopimelic acid. Succinyl-diaminopimelate desuccinylase catalyzes the removal of acyl group from N-succinyl-L,L-diaminopimelic acid to yield L,L-diaminopimelic acid. Diaminopimelate epimerase catalyzes the inversion of the α-carbon of L,L-diaminopimelic acid to yield meso-diaminopimelic acid. Siaminopimelate decarboxylase catalyzes the final step in lysine biosynthesis that removes the carbon dioxide group from meso-diaminopimelic acid to yield L-lysine.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.